PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 137 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $52,000 | -90.1% | 138,663 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $527,000 | -25.4% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $706,000 | +0.7% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $701,000 | -18.1% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $856,000 | +33.1% | 138,663 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $643,000 | +11.1% | 138,663 | +0.7% | 0.00% | 0.0% |
| Q4 2018 | $579,000 | -31.8% | 137,761 | +1.7% | 0.00% | 0.0% |
| Q3 2018 | $849,000 | -21.6% | 135,411 | +0.5% | 0.00% | -33.3% |
| Q2 2018 | $1,083,000 | +8.6% | 134,677 | +0.7% | 0.00% | +50.0% |
| Q1 2018 | $997,000 | +25.4% | 133,678 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $795,000 | +264.7% | 133,678 | +350.4% | 0.00% | +100.0% |
| Q3 2017 | $218,000 | +9.0% | 29,678 | +0.7% | 0.00% | 0.0% |
| Q2 2017 | $200,000 | -25.7% | 29,478 | +3.5% | 0.00% | 0.0% |
| Q1 2017 | $269,000 | – | 28,478 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |